REFERENCES
1. Ng OT, et al. SARS-CoV-2 seroprevalence and transmission risk
factors among high-risk close contacts: a retrospective cohort study.The Lancet Infectious Diseases 21 , 333-343 (2021).
2. Nishiura H, et al. Closed environments facilitate secondary
transmission of coronavirus disease 2019 (COVID-19). medRxiv ,
2020.2002.2028.20029272 (2020).
3. Curmei M, Ilyas A, Evans O, Steinhardt J. Estimating Household
Transmission of SARS-CoV-2. medRxiv , 2020.2005.2023.20111559
(2020).
4. Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household
Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis.JAMA Network Open 3 , e2031756-e2031756 (2020).
5. Pang X, et al. Pandemic (H1N1) 2009 among quarantined close
contacts, Beijing, People’s Republic of China. Emerging infectious
diseases 17 , 1824 (2011).
6. Spielberger BD, Goerne T, Geweniger A, Henneke P, Elling R.
Intra-Household and Close-Contact SARS-CoV-2 Transmission Among Children
- a Systematic Review. Front Pediatr 9 , 613292 (2021).
7. Liu Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan
hospitals. Nature 582 , 557-560 (2020).
8. Meselson M. Droplets and Aerosols in the Transmission of SARS-CoV-2.N Engl J Med 382 , 2063 (2020).
9. Salvatore PP, et al. Epidemiological Correlates of Polymerase
Chain Reaction Cycle Threshold Values in the Detection of Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical
Infectious Diseases 72 , e761-e767 (2020).
10. Wang W, et al. Detection of SARS-CoV-2 in Different Types of
Clinical Specimens. JAMA 323 , 1843-1844 (2020).
11. Congrave-Wilson Z, et al. Change in Saliva RT-PCR Sensitivity
Over the Course of SARS-CoV-2 Infection. JAMA 326 ,
1065-1067 (2021).
12. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for
Gastrointestinal Infection of SARS-CoV-2. Gastroenterology158 , 1831-1833.e1833 (2020).
13. Tosif S, et al. Immune responses to SARS-CoV-2 in three
children of parents with symptomatic COVID-19. Nat Commun11 , 5703 (2020).
14. Neeland MR, et al. Innate cell profiles during the acute and
convalescent phase of SARS-CoV-2 infection in children. Nat
Commun 12 , 1084 (2021).
15. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A
review of the proposed mechanisms underlying the age-related difference
in severity of SARS-CoV-2 infections. Archives of Disease in
Childhood 106 , 429-439 (2021).
16. Liu Y, Rocklöv J. The reproductive number of the Delta variant of
SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus.J Travel Med 28 , taab124 (2021).
17. Reukers DFM, et al. High infection secondary attack rates of
SARS-CoV-2 in Dutch households revealed by dense sampling.Clinical Infectious Diseases , (2021).
18. Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, Bradley
T. Cross-reactive antibody immunity against SARS-CoV-2 in children and
adults. Cell Mol Immunol 18 , 1826-1828 (2021).
19. Selva KJ, et al. Systems serology detects functionally
distinct coronavirus antibody features in children and elderly.Nat Commun 12 , 2037 (2021).
20. Majdoubi A, et al. A majority of uninfected adults show
preexisting antibody reactivity against SARS-CoV-2. JCI Insight6 , (2021).
21. Zheng S, et al. Viral load dynamics and disease severity in
patients infected with SARS-CoV-2 in Zhejiang province, China,
January-March 2020: retrospective cohort study. BMJ 369 ,
m1443 (2020).
22. Xing Y, et al. Prolonged presence of SARS-CoV-2 in feces of
pediatric patients during the convalescent phase. medRxiv ,
(2020).
23. Han MS, et al. Sequential Analysis of Viral Load in a Neonate
and Her Mother Infected With Severe Acute Respiratory Syndrome
Coronavirus 2. Clinical Infectious Diseases 71 ,
2236-2239 (2020).
24. Xu Y, et al. Characteristics of pediatric SARS-CoV-2
infection and potential evidence for persistent fecal viral shedding.Nature Medicine 26 , 502-505 (2020).
25. De Ioris MA, et al. Dynamic Viral Severe Acute Respiratory
Syndrome Coronavirus 2 RNA Shedding in Children: Preliminary Data and
Clinical Consideration from a Italian Regional Center. Journal of
the Pediatric Infectious Diseases Society 9 , 366-369 (2020).
26. Coronavirus disease (COVID-19) technical guidance: The Unity
Studies: Early Investigation Protocols. (ed^(eds).
27. Organization WH. The First Few X cases and contacts (FFX)
investigation protocol for coronavirus disease 2019 (COVID-19).
(ed^(eds). World Health Organization (2020).
28. Marcado Aea. Lessons from a national First Few “X” Household
Transmission study. In: Australasian COVID-19 Virtual Conference(ed^(eds) (2020).
29. Organization WH. Clinical management of COVID-19: interim guidance,
27 May 2020. (ed^(eds). World Health Organization (2020).
30. Quidel Corporation. Lyra® Direct SARS-CoV-2 Assay Instructions for
Use. (2021).
31. Cowley D, Donato CM, Roczo-Farkas S, Kirkwood CD. Novel G10P[14]
rotavirus strain, northern territory, Australia. Emerging
infectious diseases 19 , 1324-1327 (2013).
32. Prevention CfDCa. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time
RT-PCR Diagnostic Panel (2021).
33. Seemann T, et al. Tracking the COVID-19 pandemic in Australia
using genomics. Nature Communications 11 , 4376 (2020).
34. O’Toole Á, et al. Assignment of epidemiological lineages in
an emerging pandemic using the pangolin tool. Virus Evolution7 , (2021).
35. Selva KJ, et al. Distinct systems serology features in
children, elderly and COVID patients. medRxiv ,
2020.2005.2011.20098459 (2020).
36. McLean MR, Madhavi V, Wines BD, Hogarth PM, Chung AW, Kent SJ.
Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study
HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor
Antibodies Induced by the RV144 Vaccine Trial. J Immunol199 , 816-826 (2017).
37. Chung AW, et al. Dissecting Polyclonal Vaccine-Induced
Humoral Immunity against HIV Using Systems Serology. Cell163 , 988-998 (2015).
38. Aitken EH, et al. Developing a multivariate prediction model
of antibody features associated with protection of malaria-infected
pregnant women from placental malaria. Elife 10 , (2021).
39. Caly L, et al. Isolation and rapid sharing of the 2019 novel
coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19
in Australia. Med J Aust 212 , 459-462 (2020).
40. Houser KV, et al. Prophylaxis With a Middle East Respiratory
Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody
Protects Rabbits From MERS-CoV Infection. J Infect Dis213 , 1557-1561 (2016).